NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025
This is a contract result notice, not an open opportunity. Details from the official award data.
The procurement contact named on the official notice.
NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025<br/>CM/PHR/24/5680/01 - Tranche B for North of England and Midlands & East.
Period of Framework Agreement: 01 September 2025 to 31 August 2027 <br/>CM/PHR/24/5680/02 - Eculizumab and Ravulizumab for London & SOFE.
Period of Framework Agreement: 01 September 2025 to 31 August 2026
Make the case to bid
Reveal who to approach at NHS England, and generate a go-to-market strategy from their news, accounts and people.
Ask me about this tender, the buyer, who wins their work, or whether you should bid.
- OCID
- ocds-h6vhtk-04e273
- Stage
- award · Awarded
- Source
- Find a Tender
- Buyer ref
- 043951-2025
Contains public sector information licensed under the Open Government Licence v3.0. Source data © Crown copyright.
Who wins this kind of work
The suppliers and buyers around this opportunity — drawn from official award data. Drag to orbit; click a node to explore.
Top suppliers & buyers in Medical Equipment & Pharmaceuticals
NHS England’s tender network
Assembling the network…
Similar open tenders
NP39726 Generic and Biosimilar Cancer Medicines
The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland)
NHS Grampian Radiotherapy TPS, OMS and Archive Replacement
NHS Grampian